<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Molindone" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Molindone</book-part-id>
      <title-group>
        <title>Molindone</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>1</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Mogamulizumab" document-type="chapter">Mogamulizumab</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="MonoclonalAntibodies" document-type="chapter">Monoclonal Antibodies</related-object>
    </book-part-meta>
    <body>
      <sec id="Molindone.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Molindone.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Molindone is a conventional antipsychotic agent used in the therapy of schizophrenia. Molindone therapy is commonly associated with minor serum aminotransferase elevations but has rarely been linked to cases of clinically apparent acute liver injury.</p>
        </sec>
        <sec id="Molindone.Background">
          <title>Background</title>
          <p>Molindone (moe lin' done) is a dihydroindolone antipsychotic medication that is not structurally related to the phenothiazines and which appears to act by blocking dopamine type 2 (D2) receptors. Molindone has other central and peripheral effects including anticholinergic and alpha adrenergic blockade. Molindone was approved for use in the therapy of psychotic disorders in the United States in 1974. Since then, however, molindone has been replaced in large part by the atypical antipsychotics, which have fewer extrapyramidal side effects. Molidone is no longer frequently used, but remains available as tablets of 5, 10, 25 and 50 mg generically and previously under the brand name Moban. Recommended doses of molindone were 50 to 75 mg daily initially, increasing based upon efficacy and tolerance to as high as 225 mg daily. Common side effects included drowsiness, dizziness, headache, blurred vision, dry mouth, and tremor. Less common but potentially severe adverse events include extrapyramidal symptoms, akathisia, tardive dyskinesia, neuroleptic malignant syndrome, leukopenia, agranulocytosis, falls and excess mortality in elderly subjects with dementia.</p>
        </sec>
        <sec id="Molindone.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Liver test abnormalities have been reported to occur in a small proportion of patients on long term therapy with molindone, but elevations are uncommonly above 3 times the upper limit of normal. The aminotransferase abnormalities are usually mild, asymptomatic and transient, reversing even with continuation of medication. Instances of clinically apparent acute liver injury have been reported due to molindone, but are rare. The onset of injury is within 4 to 8 weeks, and the pattern of serum enzyme elevations is typically hepatocellular. Jaundice is uncommon and most cases are self-limited and mild. Immunoallergic features and autoantibody formation are not typical.</p>
          <p>Likelihood score: D (possible, rare cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Molindone.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The mechanism by which molindone causes serum aminotransferase elevations is not known, but is likely due to production of a toxic intermediate by its metabolism. Molindone is extensively metabolized by the liver via sulfoxidation and oxidation, but has not been implicated in clinically significant drug-drug interactions.</p>
        </sec>
        <sec id="Molindone.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>The serum aminotransferase elevations that occur on molindone therapy are usually self-limited and do not require dose modification or discontinuation of therapy. No instances of acute liver failure or vanishing bile duct syndrome due to molindone have been reported. Patients with molindone induced liver injury probably do not have cross sensitivity to atypical antipsychotics.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="AntipsychoticAgents" document-type="chapter">Antipsychotic Agents</related-object></p>
        </sec>
      </sec>
      <sec id="Molindone.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Molindone &#x02013; Generic, Moban&#x000ae;</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Antipsychotic Agents</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Molindone.CHEMICAL_FORMULA_AND_STRUCTURE">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Molindone.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Molindone.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Molindone.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Molindone.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Molindone.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Molindone.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Molindone</td>
                <td headers="hd_h_Molindone.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134987862">7416-34-4</ext-link>
                </td>
                <td headers="hd_h_Molindone.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C16-H24-N2-O2</td>
                <td headers="hd_h_Molindone.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134987862" document-id-type="sid" document-type="summary" object-id="134987862" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Molindone.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 21 January 2020</p>
        <ref-list id="Molindone.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Molindone.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Neuroleptic drugs. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 483-91.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity of neuroleptic drugs including molindone published in 1999; mentions that molindone can cause serum aminotransferase elevations and has been linked to rare cases of clinically apparent cases of liver injury).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Molindone.REF.larrey.2013">
            <mixed-citation publication-type="book">Larrey D, Ripault MP. Molindone. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 455.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of psychiatric agents mentions mentions a single case of clinically apparent liver injury due to molindone).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Molindone.REF.meyer.2018">
            <mixed-citation publication-type="book">Meyer JM. Pharmacotherapy of psychosis and mania. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 279-302.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Molindone.REF.kellner.1976.686">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kellner</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Rada</surname>
                  <given-names>RT</given-names>
                </name>
                <name name-style="western">
                  <surname>Egelman</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Macaluso</surname>
                  <given-names>B</given-names>
                </name>
              </person-group>
              <article-title>Long-term study of molindone hydrochloride in chronic schizophrenics.</article-title>
              <source>Curr Ther Res Clin Exp</source>
              <year>1976</year>
              <volume>20</volume>
              <fpage>686</fpage>
              <lpage>94</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Open label study of molindone for 6 months in 23 patients; 2 had minimal ALT elevations; no details given).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">825355</pub-id>
            </element-citation>
          </ref>
          <ref id="Molindone.REF.bhatia.1985.744">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bhatia</surname>
                  <given-names>SC</given-names>
                </name>
                <name name-style="western">
                  <surname>Banta</surname>
                  <given-names>LE</given-names>
                </name>
                <name name-style="western">
                  <surname>Ehrlich</surname>
                  <given-names>DW</given-names>
                </name>
              </person-group>
              <article-title>Molindone and hepatotoxicity.</article-title>
              <source>Drug Intell Clin Pharm</source>
              <year>1985</year>
              <volume>19</volume>
              <fpage>744</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(17 year old male developed fever and fatigue 4 weeks after starting molindone [bilirubin 0.3 mg/dL, ALT 694 U/L, Alk P 100 U/L], resolving within 3 weeks of stopping; rechallenge for 4 days led to ALT elevations [134 U/L]; patient later tolerated thioridazine; authors mention 11 previous instances of hepatotoxicity, all of which were asymptomatic and self-limited).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">4053979</pub-id>
            </element-citation>
          </ref>
          <ref id="Molindone.REF.claghorn.1985.30">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Claghorn</surname>
                  <given-names>JL</given-names>
                </name>
              </person-group>
              <article-title>Review of clinical and laboratory experiences with molindone hydrochloride.</article-title>
              <source>J Clin Psychiatry</source>
              <year>1985</year>
              <volume>46</volume>
              <issue>8 Pt 2</issue>
              <fpage>30</fpage>
              <lpage>3</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of pharmacokinetics, mechanism of action and efficacy of molindone; no mention of hepatic side effects).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3894340</pub-id>
            </element-citation>
          </ref>
          <ref id="Molindone.REF.munyon.1987.182">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Munyon</surname>
                  <given-names>WH</given-names>
                </name>
                <name name-style="western">
                  <surname>Salo</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Briones</surname>
                  <given-names>DF</given-names>
                </name>
              </person-group>
              <article-title>Cytotoxic effects of neuroleptic drugs.</article-title>
              <source>Psychopharmacology (Berl)</source>
              <year>1987</year>
              <volume>91</volume>
              <fpage>182</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(In vitro testing for cytotoxicity suggested that the phenothiazines are the most, haloperidol intermediate and loxapine and molindone the least toxic).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2883697</pub-id>
            </element-citation>
          </ref>
          <ref id="Molindone.REF.allison.1999.1686">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Allison</surname>
                  <given-names>DB</given-names>
                </name>
                <name name-style="western">
                  <surname>Mentore</surname>
                  <given-names>JL</given-names>
                </name>
                <name name-style="western">
                  <surname>Heo</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Chandler</surname>
                  <given-names>LP</given-names>
                </name>
                <name name-style="western">
                  <surname>Cappelleri</surname>
                  <given-names>JC</given-names>
                </name>
                <name name-style="western">
                  <surname>Infante</surname>
                  <given-names>MC</given-names>
                </name>
                <name name-style="western">
                  <surname>Weiden</surname>
                  <given-names>PJ</given-names>
                </name>
              </person-group>
              <article-title>Antipsychotic-induced weight gain: a comprehensive research synthesis.</article-title>
              <source>Am J Psychiatry</source>
              <year>1999</year>
              <volume>156</volume>
              <fpage>1686</fpage>
              <lpage>96</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of 81 articles on weight change with antipsychotics, using change after 10 weeks to compare agents: clozapine +5.7, olanzapine +4.2, chlorpromazine +4.2, risperidone +1.7, loxapine +0.6, haloperidol +0.5, ziprasidone +0.3, molindone -0.1, and pimozide -2.7 kg).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">10553730</pub-id>
            </element-citation>
          </ref>
          <ref id="Molindone.REF.bagnall.2007.cd002083">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bagnall</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Fenton</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Kleijnen</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Lewis</surname>
                  <given-names>R</given-names>
                </name>
              </person-group>
              <article-title>Molindone for schizophrenia and severe mental illness.</article-title>
              <source>Cochrane Database Syst Rev</source>
              <year>2007</year>
              <issue>1</issue>
              <elocation-id>CD002083</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(Cochrane review of efficacy and safety; no mention of hepatotoxicity or serum ALT elevations).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17253473</pub-id>
            </element-citation>
          </ref>
          <ref id="Molindone.REF.sikich.2008.1420">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Sikich</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Frazier</surname>
                  <given-names>JA</given-names>
                </name>
                <name name-style="western">
                  <surname>McClellan</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Findling</surname>
                  <given-names>RL</given-names>
                </name>
                <name name-style="western">
                  <surname>Vitiello</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Ritz</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Ambler</surname>
                  <given-names>D</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.</article-title>
              <source>Am J Psychiatry</source>
              <year>2008</year>
              <volume>165</volume>
              <fpage>1420</fpage>
              <lpage>31</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Prospective trial of molindone [1st generation] vs olanzapine or risperidone [2nd generation] for schizophrenia in 119 youths found similar rates of efficacy [34-50%], but more weight gain [mean 6.1 kg] and ALT elevations with olanzapine).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18794207</pub-id>
            </element-citation>
          </ref>
          <ref id="Molindone.REF.torrent.2008.4">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Torrent</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Amann</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Sanchez-Moreno</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Colom</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Feinares</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Comes</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Rosa</surname>
                  <given-names>AR</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.</article-title>
              <source>Acta Psychiatr Scand</source>
              <year>2008</year>
              <volume>118</volume>
              <fpage>4</fpage>
              <lpage>18</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of frequency of weight gain in patients treated for bipolar disorders, most weight gain occurred with clozapine and olanzapine, but some weight gain also with quetiapine, risperidone, lithium, valproate and gabapentin; little or none with molindone, loxapine, carbamazepine and lamotrigine).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18498432</pub-id>
            </element-citation>
          </ref>
          <ref id="Molindone.REF.findling.2010.583">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Findling</surname>
                  <given-names>RL</given-names>
                </name>
                <name name-style="western">
                  <surname>Johnson</surname>
                  <given-names>JL</given-names>
                </name>
                <name name-style="western">
                  <surname>McClellan</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Frazier</surname>
                  <given-names>JA</given-names>
                </name>
                <name name-style="western">
                  <surname>Vitiello</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Hamer</surname>
                  <given-names>RM</given-names>
                </name>
                <name name-style="western">
                  <surname>Lieberman</surname>
                  <given-names>JA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.</article-title>
              <source>J Am Acad Child Adolesc Psychiatry</source>
              <year>2010</year>
              <volume>49</volume>
              <fpage>583</fpage>
              <lpage>94</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(119 youths with early onset schizophrenia were treated with olanzapine, risperidone or molindone for 8 weeks and 54 were treated in a maintenance study; those on molindone showed the highest numerical increases in ALT [increase of 3-5 U/L], but there were no drug discontinuations for liver disease).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">20494268</pub-id>
            </element-citation>
          </ref>
          <ref id="Molindone.REF.stocks.2012.102">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Stocks</surname>
                  <given-names>JD</given-names>
                </name>
                <name name-style="western">
                  <surname>Taneja</surname>
                  <given-names>BK</given-names>
                </name>
                <name name-style="western">
                  <surname>Baroldi</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Findling</surname>
                  <given-names>RL</given-names>
                </name>
              </person-group>
              <article-title>A phase 2a randomized, parallel-group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems.</article-title>
              <source>J Child Adolesc Psychopharmacol</source>
              <year>2012</year>
              <volume>22</volume>
              <fpage>102</fpage>
              <lpage>11</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 78 children with attention deficit syndrome treated with 1 of 4 doses of molindone for 12 weeks, adverse events included somnolence, weight gain, akathisia, sedation and abdominal pain, and there were &#x0201c;no clinically meaningful changes in laboratory&#x0201d; findings).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22372512</pub-id>
            </element-citation>
          </ref>
          <ref id="Molindone.REF.bj_rnsson.2013.1419">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>ES</given-names>
                </name>
                <name name-style="western">
                  <surname>Bergmann</surname>
                  <given-names>OM</given-names>
                </name>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>HK</given-names>
                </name>
                <name name-style="western">
                  <surname>Kvaran</surname>
                  <given-names>RB</given-names>
                </name>
                <name name-style="western">
                  <surname>Olafsson</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland.</article-title>
              <source>Gastroenterology</source>
              <year>2013</year>
              <volume>144</volume>
              <fpage>1419</fpage>
              <lpage>25</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, none of which were attributed to antipsychotic drugs or molindone).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23419359</pub-id>
            </element-citation>
          </ref>
          <ref id="Molindone.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hern&#x000e1;ndez</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bessone</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000e1;nchez</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>di Pace</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Brahm</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Zapata</surname>
                  <given-names>R, A</given-names>
                </name>
                <name name-style="western">
                  <surname>Chirino</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, none were attributed to molindone or other antipsychotic drugs).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Molindone.REF.chalasani.2015">
            <mixed-citation publication-type="other">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52. e7. PMID: 25754159<annotation><p><italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 5 were attributed to antipsychotic agents, including olanzapine [n=2] and quetiapine [n=3] but not molindone).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Molindone.REF17">
            <element-citation publication-type="journal">
              <article-title>Drugs for psychotic disorders.</article-title>
              <source>Med Lett Drugs Ther</source>
              <year>2016</year>
              <volume>58</volume>
              <issue>1510</issue>
              <fpage>160</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise review of the mechanism of action, clinical efficacy, toxicity and costs of antipsychotic drugs, mentions that molindone is a first generation agent and is less sedative and less likely to cause extrapyramidal symptoms than haloperidol and the phenothiazines; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">27960194</pub-id>
            </element-citation>
          </ref>
          <ref id="Molindone.REF.solmi.2017.757">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Solmi</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Murru</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Pacchiarotti</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Undurraga</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Veronese</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Fornaro</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Stubbs</surname>
                  <given-names>B</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.</article-title>
              <source>Ther Clin Risk Manag</source>
              <year>2017</year>
              <volume>13</volume>
              <fpage>757</fpage>
              <lpage>77</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Safety and tolerability of antipsychotic medications in current use, mentions that liver damage is most common with chlorpromazine, olanzapine, clozapine, quetiapine and risperidone; hepatic injury related to molindone is not discussed).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28721057</pub-id>
            </element-citation>
          </ref>
          <ref id="Molindone.REF.krause.2018.659">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Krause</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Zhu</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Huhn</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Schneider-Thoma</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Bighelli</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Chaimani</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Leucht</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis.</article-title>
              <source>Eur Neuropsychopharmacol</source>
              <year>2018</year>
              <volume>28</volume>
              <fpage>659</fpage>
              <lpage>74</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Metaanalysis of published controlled trials of antipsychotic medications in children and adolescents mentions that molindone was superior to placebo and to haloperidol in studies of efficacy and was the best agent in terms of weight gain; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">29802039</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Molindone.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(Molindone/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Molindone: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Molindone">Trials on Molindone: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
